Amgen Inc. (AMGN)

The company now

Amgen reported second-quarter 2026 revenue of $10.1 billion on August 4, up 10 percent from the second quarter of 2025 1.

Twenty-two products grew sales by double digits, and seventeen are running above $1 billion a year, the company said 1. Repatha, a cholesterol drug, rose 37 percent to $953 million, and Imdelltra, a lung cancer drug, rose 115 percent to $288 million 1.

Prolia, a bone drug, fell 32 percent to $759 million as biosimilars, near copies of a biologic medicine, reached the market 1. Its U.S. patents on the antibody behind Prolia expired in February 2025 5.

On July 31, 2026, Amgen reported that unauthorized activity in cloud systems run by outside providers had let data leave, including patient health information, and that it judged the incident material on July 29 3. The company said it believes the incident is not reasonably likely to have a material impact on its financial condition or results 3.

The company also said the FDA asked it to withdraw its vasculitis drug Tavneos from the U.S. market, and it requested a hearing on June 1, 2026 1. On October 26, 2026, the board appointed David Gibbs, a former Yum Brands chief executive, bringing the board to 13 directors 4.

As of Oct 30, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.